Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate), supplied by APExBIO, is a high-purity small molecule SGLT2 inhibitor with a molecular weight of 453.52 and chemical formula C₂₄H₂₆FO_5.5S, validated by HPLC and NMR to ≥98% purity (APExBIO product page). Its mechanism is selective inhibition of sodium-glucose co-transporter 2, which blocks renal glucose reabsorption and enables excretion of glucose in urine (GeroScience 2025, DOI). It exhibits good solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) but is insoluble in water. Canagliflozin (hemihydrate) is stable at -20°C, shipped on blue ice, and is recommended for immediate use upon solution preparation due to stability constraints. Unlike mTOR inhibitors, it shows no TOR pathway inhibition in drug-sensitized yeast models (GeroScience 2025, DOI).

Biological Rationale

Type 2 diabetes mellitus and metabolic syndrome are characterized by abnormal glucose homeostasis. The kidney plays a critical role in regulating blood glucose levels by reabsorbing filtered glucose via sodium-glucose co-transporters (SGLTs). SGLT2, located in the proximal tubule of the nephron, accounts for approximately 90% of renal glucose reabsorption. Inhibiting SGLT2 reduces blood glucose by promoting glucosuria, offering a pathway distinct from insulin-centric or mTOR-mediated mechanisms (Canagliflozin (hemihydrate): SGLT2 Inhibitor for Glucose ...). This contrasts with mTOR inhibitors, which modulate cell growth and metabolism primarily via protein kinase signaling (GeroScience 2025).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) is a potent and selective inhibitor of SGLT2, a membrane protein responsible for sodium-coupled glucose reabsorption in the kidney. By binding to SGLT2, it prevents glucose uptake from the glomerular filtrate, resulting in increased urinary glucose excretion and decreased blood glucose concentrations. This mechanism is independent of insulin secretion or sensitivity. Preclinical studies confirm that Canagliflozin does not inhibit mTOR or TORC1/2 activity, even in drug-sensitized yeast models (GeroScience 2025). Its specificity enables researchers to dissect glucose metabolism and renal physiology without confounding effects on protein kinase pathways.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) demonstrates ≥98% chemical purity as established by HPLC and NMR quality control (APExBIO).
• Solubility in DMSO reaches at least 83.4 mg/mL; in ethanol, ≥40.2 mg/mL; the compound is insoluble in water (APExBIO technical data).
• Inhibition of SGLT2 by Canagliflozin blocks renal glucose reabsorption, lowering blood glucose in mammalian systems (Internal Article).
• Canagliflozin does not inhibit mTOR/TOR pathway activity in yeast-based drug-sensitized models, distinguishing it from kinase inhibitors (GeroScience 2025, DOI).
• Recommended storage is at -20°C; solutions should be used promptly and not stored long-term due to stability concerns (APExBIO).
• APExBIO supplies Canagliflozin (hemihydrate) for research use only, not for diagnostic or clinical applications (APExBIO product documentation).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is widely used in:

• Glucose metabolism and homeostasis pathway research.
• Experimental models of type 2 diabetes mellitus and metabolic disorders.
• Studies focusing on renal glucose reabsorption mechanisms.
• Screening for pathway-specific SGLT2 inhibition, avoiding mTOR pathway crosstalk (Related Article: This article provides updated benchmarks and clarifies the lack of mTOR pathway effects compared to prior analyses).
• Development of new therapeutic strategies targeting SGLT2.

Common Pitfalls or Misconceptions

• Misconception: Canagliflozin inhibits mTOR/TOR pathways.
  Clarification: No TOR inhibition detected in drug-sensitized yeast models, even at high concentrations (GeroScience 2025).
• Pitfall: Assuming water solubility for in vitro assays.
  Clarification: Compound is insoluble in water; use DMSO or ethanol for stock solutions (APExBIO).
• Pitfall: Long-term storage of stock solutions.
  Clarification: Solutions should be prepared fresh and used promptly to ensure compound integrity.
• Limitation: Not suitable for diagnostic or clinical use.
  Clarification: For research use only as per APExBIO and regulatory guidelines.
• Misconception: SGLT2 and SGLT1 inhibition are interchangeable.
  Clarification: Canagliflozin (hemihydrate) is highly selective for SGLT2, with substantially lower affinity for SGLT1.

Workflow Integration & Parameters

For experimental design, Canagliflozin (hemihydrate) is typically dissolved in DMSO or ethanol at concentrations up to 83.4 mg/mL and 40.2 mg/mL, respectively. Researchers should avoid water as a solvent due to insolubility. Stock solutions are best prepared immediately prior to use and kept at -20°C until needed (product C6434 kit). Shipping is recommended with blue ice to maintain stability. In cell-based and animal models, dosing should be optimized according to established SGLT2 inhibition protocols, taking into account species, administration route, and desired effect on glucose homeostasis (Related Article: This article expands on molecular specificity and experimental nuances not addressed in the current piece).

Conclusion & Outlook

Canagliflozin (hemihydrate) from APExBIO stands as a gold-standard reagent for dissecting SGLT2-mediated glucose reabsorption and metabolic pathways. Its validated specificity, high purity, and robust solubility profile make it indispensable for research in diabetes mellitus and metabolic disorders. Benchmarking against mTOR inhibitors affirms its distinct mechanism and utility for pathway-specific studies. For further methodological guidance and troubleshooting, see this article, which details workflow integration and addresses advanced use-cases beyond the scope of this review.